Education
About Us
Working with TipRanks
Follow Us
Novavax (NVAX)
:NVAX
Earnings Data
Report Date
Aug 06, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.05Last Year’s EPS
0.99Same Quarter Last Year
Based on 5 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 08, 2025
|% Change Since: 0.50%
|Next Earnings Date:Aug 06, 2025
Earnings Call Sentiment|Neutral
The call reflects significant revenue growth and successful cost reduction strategies, alongside strategic partnerships and pipeline advancements. However, challenges remain with regulatory commitments and market penetration for existing products.Company Guidance
During the Novavax First Quarter 2025 Financial Results and Operational Highlights Conference Call, the company provided a detailed overview of its strategic priorities and financial performance. The call highlighted a significant revenue increase to $667 million, largely due to the recognition of $603 million from the closure of agreements with Canada and New Zealand. The company reiterated its full-year financial guidance, projecting combined R&D and SG&A expenses between $475 million and $525 million and increased its 2025 revenue framework to between $975 million and $1,025 million. Novavax emphasized its progress in reducing costs, cutting combined R&D and SG&A expenses by 24% year-over-year, and highlighted its strategic focus on partnerships, including an amended agreement with Takeda and ongoing collaboration with Sanofi. The company aims for non-GAAP profitability by 2027 and sees potential catalysts this year, such as FDA approval for its COVID-19 vaccine BLA and advancements in its early-stage pipeline.Revenue Surge
Novavax reported total revenue of $667 million for the first quarter of 2025, a significant increase from $94 million in the same quarter of 2024. This includes $622 million in product sales, primarily from the termination of agreements with Canada and New Zealand.
Cost Reduction Success
The company reduced combined R&D and SG&A expenses by 24% compared to the previous year, with a significant 45% reduction in SG&A costs.
Strategic Partnerships
Strengthened partnership with Takeda for the Japanese market and ongoing collaborations with Sanofi and other pharmaceutical companies to advance pipeline and technology platform.
Positive Phase 3 Enrollment
Completion of enrollment of approximately 2,000 participants in a Phase 3 trial for CIC and standalone flu vaccine candidates.
New Early-Stage Pipeline Programs
Initiation of four early-stage programs, including H5N1, RSV combinations, shingles, and C. Difficile.
---
NVAX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
NVAX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 08, 2025 | $5.95 | $6.66 | +11.93% |
Feb 27, 2025 | $7.32 | $7.06 | -3.55% |
Nov 12, 2024 | $9.01 | $8.46 | -6.10% |
Aug 08, 2024 | $10.71 | $11.68 | +9.06% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Novavax (NVAX) report earnings?
Novavax (NVAX) is schdueled to report earning on Aug 06, 2025, TBA Not Confirmed.
What is Novavax (NVAX) earnings time?
Novavax (NVAX) earnings time is at Aug 06, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is NVAX EPS forecast?
NVAX EPS forecast for the fiscal quarter 2025 (Q2) is -0.05.
---
